Stockreport

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Voyager Therapeutics, Inc.  (VYGR) 
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.voyagertherapeutics.com
PDF - Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, [Read more]